eli lilly novo nordisk - Search News

News

Novo Nordisk to sell weight-loss drug for $499

Barron's on MSN · 2d

This Weight-Loss Stock Is Down 40%. It Lowers the Risks for Eli Lilly and Novo Nordisk.

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Seeking Alpha · 3d

Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly and Company (LLY) for long-term growth.

Fox Business on MSN · 3d

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.

5d

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

13don MSN

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

2d

Novo Nordisk: Negative Streak Finally Ended

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

10d

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...

1don MSN

Drugmaker Novo Nordisk freezes hiring for non-critical jobs

Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...

1d

Novo Nordisk: Cleared For A Climb

Novo Nordisk is a sector leader in the fast-growing GLP-1 market, boasting strong fundamentals. Click here to read why I rate ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results